6785 Stock Overview
Alar Pharmaceuticals Inc. operates as a drug development company.
Alar Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$43.90|
|52 Week High||NT$55.30|
|52 Week Low||NT$42.80|
|1 Month Change||-7.19%|
|3 Month Change||-11.85%|
|1 Year Change||-11.67%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-2.44%|
Recent News & Updates
We're Hopeful That Alar Pharmaceuticals (GTSM:6785) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|6785||TW Pharmaceuticals||TW Market|
Return vs Industry: 6785 underperformed the TW Pharmaceuticals industry which returned 3% over the past year.
Return vs Market: 6785 underperformed the TW Market which returned 0.7% over the past year.
|6785 Average Weekly Movement||6.2%|
|Pharmaceuticals Industry Average Movement||5.4%|
|Market Average Movement||4.6%|
|10% most volatile stocks in TW Market||8.3%|
|10% least volatile stocks in TW Market||2.1%|
Stable Share Price: 6785 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 6785's weekly volatility (6%) has been stable over the past year.
About the Company
Alar Pharmaceuticals Inc. operates as a drug development company. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which primarily include opioid use disorder, chronic pain, and major depressive disorder. The company is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid addiction; and ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression.
Alar Pharmaceuticals Fundamentals Summary
|6785 fundamental statistics|
Is 6785 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6785 income statement (TTM)|
|Cost of Revenue||NT$0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.13|
|Net Profit Margin||0.00%|
How did 6785 perform over the long term?See historical performance and comparison
Is Alar Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6785's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6785's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: 6785 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.
PE vs Market: 6785 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6785's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6785 is overvalued based on its PB Ratio (4.7x) compared to the TW Pharmaceuticals industry average (2x).
How is Alar Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Alar Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Alar Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6785 is currently unprofitable.
Growing Profit Margin: 6785 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6785 is unprofitable, and losses have increased over the past 5 years at a rate of 15.3% per year.
Accelerating Growth: Unable to compare 6785's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6785 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).
Return on Equity
High ROE: 6785 has a negative Return on Equity (-12.02%), as it is currently unprofitable.
How is Alar Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 6785's short term assets (NT$528.7M) exceed its short term liabilities (NT$4.5M).
Long Term Liabilities: 6785's short term assets (NT$528.7M) exceed its long term liabilities (NT$1.1M).
Debt to Equity History and Analysis
Debt Level: 6785 is debt free.
Reducing Debt: 6785 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6785 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6785 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 6.7% each year
What is Alar Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6785's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6785's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6785's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6785's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 6785 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Dr. Yung-Shun Wen, Ph D., is Chief Executive Officer & Director of Alar Pharmaceuticals Inc. He has experiences in the pharmaceutical industry When he was a director of RD department in a well-known pharma...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Alar Pharmaceuticals Inc.'s employee growth, exchange listings and data sources
- Name: Alar Pharmaceuticals Inc.
- Ticker: 6785
- Exchange: TPEX
- Founded: 2016
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NT$2.502b
- Shares outstanding: 57.00m
- Website: https://www.alarpharm.com
Number of Employees
- Alar Pharmaceuticals Inc.
- No. 19, Keyuan Road
- Rm. 312, 3rd Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.